Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MSMZ | ISIN: US03152W1099 | Ticker-Symbol: AM6
Tradegate
06.06.25 | 16:51
5,350 Euro
-0,93 % -0,050
1-Jahres-Chart
AMICUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
AMICUS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,3505,45006.06.
5,3505,45006.06.

Aktuelle News zur AMICUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoAMICUS THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans1
AMICUS THERAPEUTICS Aktie jetzt für 0€ handeln
DoAMICUS THERAPEUTICS, INC. - 8-K, Current Report1
DiAmicus Therapeutics, Inc.: New Analysis of Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) Published in Muscle and Nerve78PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL...
► Artikel lesen
01.05.AMICUS THERAPEUTICS, INC. - 8-K, Current Report4
01.05.Dimerix and Amicus Therapeutics partner to commercialise kidney disease treatment DMX-200 in the US4
01.05.Amicus Therapeutics, Inc.; Dimerix Limited: Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States135Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney...
► Artikel lesen
30.04.Amicus Therapeutics Q1 2025 Earnings Preview2
30.04.Amicus Therapeutics Earnings Preview1
23.04.Amicus Therapeutics to Report Q1 Earnings: What's in the Cards?7
21.04.Amicus Therapeutics, Inc.: Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 20253
13.03.Amicus Therapeutics, Inc. (FOLD): Among the Stocks Under $10 With High Upside Potential4
19.02.Amicus Therapeutics files for potential mixed shelf offering2
19.02.AMICUS THERAPEUTICS, INC. - 10-K, Annual Report-
19.02.BofA cuts Amicus Therapeutics stock target to $14, keeps Buy rating4
19.02.Amicus Therapeutics beats FY topline estimates2
19.02.Amicus Therapeutics, Inc.: Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates1792024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and...
► Artikel lesen
19.02.AMICUS THERAPEUTICS, INC. - 8-K, Current Report-
18.02.Amicus Therapeutics FY 2024 Earnings Preview3
10.02.Amicus Therapeutics, Inc.: Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 20252
03.02.Amicus Therapeutics, Inc.: Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium 20252
Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1